Melanotan I
Also known as: MT-1, Afamelanotide, CUV1647, Scenesse
Melanotan I (Afamelanotide) is an FDA Breakthrough Therapy and EU-approved (Scenesse) selective MC1R agonist used to prevent phototoxic skin reactions in patients with erythropoietic protoporphyria (EPP). Unlike Melanotan II, its linear structure and MC1R selectivity provide a more targeted and safer melanogenic effect.
Regulatory & Approval Status
Melanotan I (afamelanotide) has undergone extensive clinical testing, including Phase 3 trials. While it is approved in some international jurisdictions (e.g., EU/Australia) for specific conditions, it is not FDA-approved for general use in the United States.
Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.